8 June 2021 - First approval of a conjugate vaccine that helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia, including seven responsible for 40% of pneumococcal disease cases and deaths in the U.S.

Pfizer announced today that the U.S. FDA has approved Prevnar 20 (pneumococcal 20 valent conjugate vaccine) for the prevention of invasive disease and pneumonia caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes in the vaccine in adults ages 18 years and older. 

Following today’s FDA approval, the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices is expected to meet in October to discuss and update recommendations on the safe and appropriate use of pneumococcal vaccines in adults.

Read Pfizer press release